Stents Bioresorbable

This channel includes news and new technology innovations for bioresorbable stents (BRS). These devices are also referred to as bioabsorbable stents, bioresorbable scaffolds and dissolving stents. BRS are designed as an alternative to permanent metallic stent implants, which cause issues in a small number of patients with in-stent restenosis, late-stent thrombosis and require use of long-term antiplatelet therapy. Metallic stents also cause issues with CT and MRI imaging and may prevent future options for coronary bypass graft (CABG) surgery. BRS are supposed to remove avoid these issues by dissolving and disappearing from the vessel after a period of 2-4 years. This, returns the vessel to its natural state and allows for the return of vasodilatation and vasoconstriction. BRS have had some issues in clinical trials not being able to match the performance of standard metallic drug eluting stents (DES) because of their thick stent struts. Newer generation BRS are in development with struts smaller than 100 micros, with will be closer to those of current generation metallic stents

 

Abbott, Absorb bioresorbable stent, BVS, FDA advisory panel approval
Feature | Stents Bioresorbable | Dave Fornell

March 15, 2016 — An independent panel of experts convened by the U.S. Food and Drug Administration (FDA) voted 9 to 0 ...

Home March 15, 2016
Home
News | Stents Bioresorbable

March 11, 2016 — Magnesium Elektron, developer, manufacturer and supplier of high-performance magnesium alloys ...

Home March 11, 2016
Home
Blog

At the beginning of each year, I always try to determine what the next big cardiovascular technology advances to watch ...

Home January 20, 2016
Home
News | Cath Lab | Dave Fornell

The U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel is set to review data and offer ...

Home January 20, 2016
Home
Blog | Cath Lab

For the past few years, the focus of the annual Transcatheter Cardiovascular Therapeutics (TCT) meetings has been on ...

Home November 05, 2015
Home
Videos | TCT

DAIC Editor Dave Fornell offers his choices for the most innovative new interventional cardiovascular technologies ...

Home November 05, 2015
Home
Videos | TCT

Tom Watson, clinical analyst for MDBuyLine, and DAIC Editor Dave Fornell discuss some of the new cardiovascular and ...

Home November 05, 2015
Home
News | Stents Bioresorbable

October 30, 2015 — Results from a clinical trial showed that that the Abbott Absorb everolimus-eluting bioresorbable ...

Home October 30, 2015
Home
Videos | Stents Bioresorbable

Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, and a lead investigator for ...

Home October 30, 2015
Home
News | Stents Drug Eluting

October 27, 2015 — Results from the multicenter, prospective, randomized PANDA III trial indicate that the BuMA sirolimu ...

Home October 27, 2015
Home
Amaranth Fortitute Bioresorbable stent
Feature | TCT | Tom Watson, BS, RCVT, Clinical Analyst, MD Buyline

There were several overarching technology trends seen at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual ...

Home October 19, 2015
Home
News | Stents Bioresorbable

October 16, 2015 — Enrollment has successfully concluded in its multi-center, international CE mark clinical trials MEND ...

Home October 16, 2015
Home
ABSORB III trial, TCT 2015, bioresorbable vascular scaffold, BVS
Feature | Stents Bioresorbable

October 16, 2015 — Results from a clinical trial showed that Abbott's Absorb everolimus-eluting bioresorbable vascular ...

Home October 16, 2015
Home
News | Stents Bioresorbable

October 15, 2015 — Two new advances in stent technology announced in recent days further reinforce the effectiveness of ...

Home October 15, 2015
Home
News | Stents Bioresorbable

October 15, 2015 — Biotronik has announced results from the BIOSOLVE-II trial, investigating the safety and clinical ...

Home October 15, 2015
Home
Subscribe Now